Many studies have shown that using immune checkpoint inhibitors to block the PD-1/PD-L1 signaling pathway reversed the immunosuppression of the TME, restored T-cell antitumor activity, and enhanced tumor immunotherapy (109, 110). This evidence concerns the gene CD274 and neoplasm.